Form 8-K

8-K — LABCORP HOLDINGS INC.

Accession: 0000920148-26-000162

Filed: 2026-07-30

Period: 2026-07-30

CIK: 0000920148

SIC: 8071 (SERVICES-MEDICAL LABORATORIES)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — lh-20260730.htm (Primary)

EX-99.1 (form8-kexhibit9912q26.htm)

GRAPHIC (labcorp_logoxhorizontalxcoa.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: lh-20260730.htm · Sequence: 1

lh-20260730

0000920148false00009201482026-07-302026-07-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

July 30, 2026

(Date of earliest event reported)

LABCORP HOLDINGS INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware 1-11353 99-2588107

(State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

358 South Main Street

Burlington , North Carolina 27215

(Address of principal executive offices) (Zip Code)

(Registrant’s telephone number including area code) 336-229-1127

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class Trading Symbol Name of exchange on which registered

Common Stock, $0.10 par value LH New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

Item 9.01. Financial Statements and Exhibits.

Exhibit Exhibit Name

Exhibit 99.1

Press Release dated July 30, 2026 issued by Labcorp titled “Labcorp Announces 2026 Second Quarter Results”

Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABCORP HOLDINGS INC.

Registrant

Date: July 30, 2026 By: /s/ KATHRYN W. KYLE

Kathryn W. Kyle

Executive Vice President, Chief Legal Officer and Corporate Secretary

EX-99.1

Filename: form8-kexhibit9912q26.htm · Sequence: 2

Document

FOR IMMEDIATE RELEASE

Contact: Dewey Steadman - Investors Racquel White - Media

Investor@labcorp.com Media@labcorp.com

Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance

•Results from operations for second quarter 2026 versus second quarter 2025:

◦Revenue: $3.73 billion vs. $3.53 billion, up 5.8%

◦Diluted EPS: $3.64 vs. $2.84, up 28.5%

◦Adjusted EPS: $4.99 vs. $4.35, up 14.9%

•Raised full-year enterprise revenue growth and adjusted EPS guidance:

◦Annual revenue growth guidance of 5.4% to 6.3%; up 30 basis points at the midpoint

◦Adjusted EPS range of $18.10 to $18.55; up 30 cents at the midpoint

•Announced $1.0 billion increase in share repurchase authorization, bringing the remaining total authorization to $1.4 billion

•Advanced Labcorp Oncology offerings in lung, colorectal, and prostate cancers, expanding access to screening, improving diagnosis, guiding treatment selection, and monitoring recurrence

•Announced the launch of Marker by Labcorp™, a genetic health panel that provides consumers with personalized genetic insights

BURLINGTON, N.C., July 30, 2026 – Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the second quarter ended June 30, 2026 and updated its full-year financial guidance.

“Labcorp delivered another very strong quarter, with 6% revenue growth, significant margin expansion, and double-digit adjusted EPS growth reflecting continued momentum across the business,” said Adam Schechter, Chairman and CEO of Labcorp. “During the second quarter, we expanded our leadership in oncology and other high-growth specialty areas, strengthened our position as the partner of choice for health systems, biopharmaceutical companies, and regional/local laboratories, and advanced our use of technology to improve the experience for consumers and providers. Our performance and continued execution position us well to deliver sustainable growth and long-term value for customers and shareholders.”

Labcorp continues to advance its strategic priorities:

Lead in specialty testing, with several advancements in Labcorp Oncology:

•Added an advanced DPYD genotyping test that helps identify patients at risk for severe chemotherapy treatment-related toxicity.

•Launched ColoSense® nationwide, the first FDA-approved, RNA-based colorectal cancer screening test with at-home collection. With Medicare and expanding commercial payer coverage, this test increases patient access to screening and enables earlier detection. As ColoSense’s primary nationwide distributor, we are further strengthening our comprehensive colorectal cancer portfolio.

•Entered into a clinical trial collaboration with Fox Chase Cancer Center to evaluate Labcorp’s Plasma Detect Genome MRD in patients at risk of early-stage non-small cell lung cancer recurrence.

•Expanded nationwide access to Roche’s FDA-approved VENTANA PTEN (SP218) companion diagnostic for people living with prostate cancer who may now be eligible for combination treatment with AstraZeneca’s targeted therapy TRUQAP.

Be a partner of choice for health systems and regional/local laboratories:

•Awarded once again a Department of Defense contract to provide laboratory testing for service members and their families across military hospitals worldwide.

•Completed the acquisition of select outreach laboratory services from Parkview Health in Indiana and Ohio.

•Completed the acquisition of Tribal Diagnostics, a clinical laboratory serving communities in Oklahoma and Texas.

Grow Consumer Health:

•Announced the Marker by Labcorp Genetic Health Panel through Labcorp OnDemand where consumers can get their biomarker and genetic testing and insights from a single source.

•Introduced Canada's first at-home, self-collection test to measure women’s fertility-related hormones and men’s testosterone levels.

•Launched an AI-powered app, MyLabcorp, which has been downloaded by millions of consumers. The app allows patients to schedule appointments, view their test results, and gain deeper insights into their health.

Shape our future through technology and innovation:

•Expanded a collaboration with Epic to place 6,500-plus diagnostic tests on Epic’s Aura platform.

•Enhanced the patient experience at Labcorp’s Patient Service Centers, through expanded appointment availability, streamlined scheduling, and proactive rescheduling reminders and assistance.

Labcorp also remains committed to a disciplined allocation of capital. In the second quarter of 2026, the company invested $225.7 million in acquisitions, repurchased $353.8 million of stock, and paid out $58.7 million in dividends. The company also paid down $500.0 million in senior notes in June. On July 9, 2026, the company announced a quarterly cash dividend of $0.72 per share of common stock, payable on September 11, 2026, to stockholders of record at the close of business on August 28, 2026. In July, the Board of Directors approved an increase of $1.0 billion in the company's share repurchase authorization, bringing the remaining total authorization to $1.4 billion.

LABCORP HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED RESULTS

Three Months Ended June 30, Six Months Ended June 30,

2026 2025 Delta 2026 2025 Delta

Revenue Summary (Dollars in millions)

Total Revenue $ 3,731.1 $ 3,527.3 5.8 % $ 7,268.7 $ 6,872.4 5.8 %

Organic(1)

4.2 % 3.6 %

Acquisitions, net of Divestitures(2)

1.2 % 1.3 %

Foreign Exchange 0.4 % 0.9 %

(1) Excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in Early Development.

(2) Includes the impact from strategic actions taken in Early Development.

Earnings Summary (Dollars in millions, except per share data)

Operating Income (“OI”) $ 451.6 $ 394.5 $ 832.4 $ 720.5

OI as % of Revenue 12.1 % 11.2 % 90 bps 11.5 % 10.5 % 100 bps

Adjustments (3)

$ 137.1 $ 137.1 $ 264.2 $ 280.1

Adjusted Operating Income (“AOI”) (4)

$ 588.7 (5) $ 531.6 $ 1,096.6 $ 1,000.6

AOI as % of Revenue 15.8 % (5) 15.1 % 70 bps 15.1 % 14.6 % 50 bps

Net Earnings Attributable to Labcorp Holdings Inc. $ 298.7 $ 237.9 $ 576.5 $ 450.7

Diluted EPS $ 3.64 $ 2.84 $ 6.99 $ 5.36

Adjusted EPS (4)

$ 4.99 $ 4.35 14.9 % $ 9.24 $ 8.19 12.8 %

(3) Adjustments include amortization, impairment charges, restructuring charges, and special items.

(4) Non-GAAP financial measure. See “Reconciliation of Non-GAAP Measures” for additional information.

(5) The increase in adjusted operating income and margin was due to organic growth and operating efficiencies.

LABCORP HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED RESULTS

Three Months Ended June 30, Six Months Ended June 30,

2026 2025 2026 2025

Cash Flow Summary (Dollars in millions)

Operating Cash Flow $ 445.5 $ 620.6 $ 637.0 $ 639.1

Capital Expenditures 131.6 77.9 252.6 203.9

Free Cash Flow $ 313.9 (1) $ 542.7 $ 384.4 $ 435.2

(1) The difference in free cash flow was primarily due to working capital timing and planned increases in capital expenditures.

Capital Allocation Summary

•At the end of the quarter, Labcorp's cash and cash equivalents balance was $141.8 million and total debt was $5.86 billion. In June, we retired $500.0 million in senior notes.

•During the quarter, the company invested $225.7 million in acquisitions, repurchased $353.8 million of stock, and paid out $58.7 million in dividends.

LABCORP HOLDINGS INC. AND SUBSIDIARIES

Diagnostics Laboratories Segment Summary

Three Months Ended June 30,

2026 2025 Delta

Revenue Summary (Dollars in millions)

Total Revenue $ 2,900.7 $ 2,748.8 5.5 %

Organic 3.6 %

Acquisitions, net of Divestitures 1.9 %

Earnings Summary (1) (Dollars in millions)

Adjusted Operating Income (“AOI”) (2)

$ 522.6 (3) $ 482.8

AOI as % of Revenue 18.0 % (3) 17.6 % 50 bps

(1) Non-GAAP financial measure. See “Reconciliation of Non-GAAP Measures” for additional information.

(2) Excludes amortization, restructuring charges, special items, and unallocated corporate expenses.

(3) Adjusted Operating Income and margin increased due to organic growth and operating efficiencies.

Three Months Ended June 30, 2026

Requisition Price/Mix

Volume Delta (4)

Delta (4)

Metrics Summary

Total 3.0 % 2.5 %

Organic (5)

1.8 % 1.8 %

Acquisitions, net of Divestitures 1.3 % 0.6 %

Foreign Exchange — % — %

(4) Column shows changes versus the three months ended June 30, 2025.

(5) Organic price/mix includes lab management agreements.

LABCORP HOLDINGS INC. AND SUBSIDIARIES

Biopharma Laboratory Services Segment Summary

Three Months Ended June 30,

2026 2025 Delta

Revenue Summary (Dollars in millions)

Total Revenue $ 836.2 $ 784.8 6.5 %

(1)

Organic(2)

6.2 %

Acquisitions, net of Divestitures(3)

(1.4) %

Foreign Exchange 1.8 %

(1) Central Labs revenue growth of 9.8%; Early Development revenue was down 1.4%.

(2) Excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in Early Development.

(3) Includes the impact from strategic actions taken in Early Development.

Earnings Summary (4) (Dollars in millions)

Adjusted Operating Income (“AOI”) (5)

$ 142.2

(6)

$ 123.3

AOI as % of Revenue 17.0 %

(6)

15.7 % 130 bps

(4) Non-GAAP financial measure. See “Reconciliation of Non-GAAP Measures” for additional information.

(5) Excludes amortization, restructuring charges, special items, and unallocated corporate expenses.

(6) Adjusted Operating Income and margin increased, driven by organic growth and operating efficiencies from the strategic actions taken in Early Development.

As of

June 30, 2026

Metrics Summary (Dollars in billions)

TTM Net Orders $ 3.32

TTM Book to Bill 1.03

Backlog $ 8.73

(7)

Next Twelve Months Forecast Backlog Conversion $ 2.75

(7) Backlog increased 0.2% compared to this period last year.

Guidance for 2026

Labcorp is updating 2026 full year guidance to reflect its second quarter performance and full year outlook. The following guidance assumes foreign exchange rates effective as of June 30, 2026. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases, and dividends.

(Dollars in millions, except per share data)

Previous Updated

2026 Guidance

Low High Low High

Revenue

Labcorp Enterprise (1)(2)

$14,649 $14,803 $14,710 $14,827

Growth (3)

5.0% 6.1% 5.4% 6.3%

Diagnostics Laboratories $11,431 $11,518 $11,450 $11,532

Growth (3)

5.1% 5.9% 5.3% 6.0%

Biopharma Laboratory Services (4)

$3,216 $3,266 $3,269 $3,300

Growth (3)

3.8% 5.4% 5.5% 6.5%

Adjusted EPS $17.70 $18.35 $18.10 $18.55

Free Cash Flow $1,240 $1,360 $1,240 $1,360

(1) 2026 Updated Enterprise guidance includes an impact from foreign currency translation of 0.4%.

(2) Enterprise level revenue is presented net of intercompany transaction eliminations.

(3) Growth based on 2025 Enterprise revenue of $13,952 million, Diagnostics Laboratories revenue of $10,876 million, and Biopharma Laboratory Services revenue of $3,098 million.

(4) 2026 Updated Biopharma Laboratory Services guidance includes an impact from foreign currency translation of 1.5%.

Use of Adjusted Measures

The company has provided in this press release and accompanying tables “adjusted” financial information that has not been prepared in accordance with GAAP, including adjusted net income, adjusted EPS (or adjusted net income per share), adjusted operating income, adjusted operating margin, free cash flow, and certain segment information. The company believes these adjusted measures are useful to investors as a supplement to, but not as a substitute for, GAAP measures, in evaluating the company’s operational performance. The company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in evaluating operating results and trends, and growth and shareholder returns, as well as in comparing the company’s financial results with the financial results of other companies. However, the company notes that these adjusted measures may be different from and not directly comparable to the measures presented by other companies. Reconciliations of these non-GAAP measures to the most comparable GAAP measures and an identification of the components that comprise “special items” used for certain adjusted financial information are included in the tables accompanying this press release.

The company today is providing an investor relations presentation with additional information on its business and operations, which is available in the investor relations section of the company's website at https://ir.labcorp.com. Analysts and investors are directed to the website to review this supplemental information.

A webcast discussing Labcorp's quarterly results will be held today at 9:00 a.m. ET and is available by accessing the Labcorp investor relations website and navigating to the “Events” section. Alternatively, the live webcast can be accessed on this link. This webcast will be archived and accessible for one year.

About Labcorp

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2026 guidance and related assumptions, (ii) the impact of various factors on operating and financial results, including global economic and market conditions on the company's businesses, operating results, cash flows and/or financial condition, (iii) future business strategies, (iv) expected savings, synergies and other benefits to the company, customers or patients from acquisitions and other transactions and partnerships, and (v) opportunities for future growth.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control, including without limitation: (i) the failure to receive tax-free treatment with respect to the spin-off of the company’s former Clinical Development and Commercialization Services business for U.S. federal income purposes; (ii) the impact of spin-off related items; (iii) personnel costs and potential difficulties with employee relations and retention; (iv) the trading price of the company's stock, competitive actions and other unforeseen changes and general uncertainties in the marketplace; (v) the impact of changes to existing or adoption of new laws and regulations applicable to the company, including healthcare reform, or changes to the interpretation and application of such laws and regulations; (vi) customer purchasing decisions, including changes in payer regulations or policies; (vii) adverse actions of governmental and third-party payers; (viii) changes in testing guidelines or recommendations; (ix) the impact of global geopolitical events; (x) the effect of public opinion on the company's reputation; (xi) adverse results in material litigation matters; (xii) failure to maintain or develop customer relationships; (xiii) the company's ability to develop or acquire new products and adapt to technological changes; (xiv) failure of the company’s information technology, systems, or data security; (xv) the impact of potential losses under repurchase agreements; (xvi) adverse weather conditions; (xvii) the number of revenue days in a financial period; (xviii) inflation; (xix) increased competition; and (xx) the effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading “MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS”.

- End of Text -

- Tables to Follow -

LABCORP HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(In Millions, Except Per Share Data)

Three Months Ended June 30, Six Months Ended June 30,

2026 2025 2026 2025

Revenues $ 3,731.1 $ 3,527.3 $ 7,268.7 $ 6,872.4

Cost of revenues 2,619.1 2,481.1 5,142.9 4,878.2

Gross profit 1,112.0 1,046.2 2,125.8 1,994.2

Selling, general, and administrative expenses 577.2 579.3 1,128.2 1,125.3

Amortization of intangibles and other assets 78.1 68.3 153.7 137.9

Restructuring and other charges 5.1 4.1 11.5 10.5

Operating income 451.6 394.5 832.4 720.5

Other (expense) income:

Interest expense (61.1) (57.1) (116.2) (113.1)

Investment income 5.6 1.7 17.8 8.2

Equity method loss, net (6.2) (1.7) (11.3) (2.0)

Other, net (3.5) (32.7) (16.6) (33.7)

Earnings from operations before income taxes 386.4 304.7 706.1 579.9

Provision for income taxes 87.3 66.4 129.0 128.6

Net earnings 299.1 238.3 577.1 451.3

Less: Net earnings attributable to the noncontrolling interest (0.4) (0.4) (0.6) (0.6)

Net earnings attributable to Labcorp Holdings Inc. $ 298.7 $ 237.9 $ 576.5 $ 450.7

Earnings per common share:

Basic earnings per common share $ 3.66 $ 2.85 $ 7.03 $ 5.40

Diluted earnings per common share $ 3.64 $ 2.84 $ 6.99 $ 5.36

Weighted-average basic common shares outstanding 81.7 83.4 82.0 83.5

Weighted-average diluted common shares outstanding 82.0 83.9 82.4 84.1

LABCORP HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In Millions)

June 30, 2026 December 31, 2025

ASSETS

Current assets:

Cash and cash equivalents $ 141.8 $ 532.3

Accounts receivable, net 2,342.4 2,103.8

Unbilled services, net 162.4 156.9

Supplies inventory 562.2 534.7

Prepaid expenses and other 606.1 692.8

Total current assets 3,814.9 4,020.5

Property, plant, and equipment, net 3,100.5 3,081.5

Goodwill, net 7,030.1 6,789.5

Intangible assets, net 3,678.2 3,596.0

Joint venture partnerships and equity method investments 139.3 153.9

Other assets, net 769.3 751.3

Total assets $ 18,532.3 $ 18,392.7

LIABILITIES AND SHAREHOLDERS’ EQUITY

Current liabilities:

Accounts payable $ 688.5 $ 840.8

Accrued expenses and other 862.4 847.8

Unearned revenue 387.8 439.1

Short-term operating lease liabilities 180.3 191.1

Short-term finance lease liabilities 4.7 4.6

Short-term borrowings and current portion of long-term debt 0.9 500.1

Total current liabilities 2,124.6 2,823.5

Long-term debt 5,857.6 5,084.6

Operating lease liabilities 661.0 682.6

Finance lease liabilities 61.6 63.0

Deferred income taxes and other tax liabilities 486.7 454.5

Other liabilities 717.6 647.8

Total liabilities 9,909.1 9,756.0

Commitments and contingent liabilities

Noncontrolling interest 16.4 16.9

Shareholders’ equity:

Common stock, 80.9 and 82.2 shares outstanding at June 30, 2026, and December 31, 2025, respectively

7.3 7.5

Additional paid-in capital — —

Retained earnings 8,701.4 8,639.9

Accumulated other comprehensive loss (101.9) (27.6)

Total shareholders’ equity 8,606.8 8,619.8

Total liabilities and shareholders’ equity $ 18,532.3 $ 18,392.7

LABCORP HOLDINGS INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Millions)

Three Months Ended June 30, Six Months Ended June 30,

2026 2025 2026 2025

CASH FLOWS FROM OPERATING ACTIVITIES:

Net earnings $ 299.1 $ 238.3 $ 577.1 $ 451.3

Adjustments to reconcile net earnings to net cash provided by operating activities:

Depreciation and amortization 179.0 170.3 352.3 337.1

Stock compensation 34.9 34.1 66.6 66.9

Operating lease right-of-use asset expense 49.1 50.8 97.1 99.4

Deferred income taxes 24.4 (6.1) 26.4 (12.2)

Other, net 14.2 38.0 25.6 46.1

Change in assets and liabilities (net of effects of acquisitions and divestitures):

(Increase) decrease in accounts receivable (59.2) 30.9 (247.1) (139.9)

(Increase) decrease in unbilled services (0.7) 0.9 (6.9) 4.8

Increase in supplies inventory (65.1) (11.9) (29.7) (3.5)

Decrease in prepaid expenses and other 23.1 12.8 27.1 57.8

(Decrease) increase in accounts payable (11.7) 67.0 (150.4) (80.6)

(Decrease) increase in unearned revenue (17.6) 0.2 (49.7) (8.7)

Decrease in accrued expenses and other (24.0) (4.7) (51.4) (179.4)

Net cash provided by operating activities 445.5 620.6 637.0 639.1

CASH FLOWS FROM INVESTING ACTIVITIES:

Capital expenditures (131.6) (77.9) (252.6) (203.9)

Proceeds from sale of assets 1.9 1.9 9.7 2.4

Proceeds from sale or distribution of equity affiliates or other investments — 6.9 — 6.9

Purchase of equity affiliates or other investments (10.8) (15.0) (17.5) (172.0)

Acquisition of businesses, net of cash acquired (225.7) (10.0) (427.9) (63.5)

Net cash used for investing activities (366.2) (94.1) (688.3) (430.1)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from term loan — — 750.0 —

Payments on senior notes (500.0) — (500.0) (1,000.0)

Proceeds from accounts receivable securitization 175.0 — 175.0 225.0

Payments on accounts receivable securitization (150.0) — (150.0) —

Proceeds from revolving credit facilities — — — 64.8

Payments on revolving credit facilities — — — (64.8)

Net share settlement tax payments from issuance of stock to employees (6.3) (3.5) (46.1) (29.0)

Net proceeds from issuance of stock to employees 1.8 — 34.7 25.7

Dividends paid (58.7) (59.9) (119.9) (121.5)

Purchase of common stock (353.8) (200.0) (451.8) (200.0)

Other, net (27.9) (4.0) (31.3) (7.3)

Net cash used for financing activities (919.9) (267.4) (339.4) (1,107.1)

Effect of exchange rate on changes in Cash and cash equivalents 1.3 18.8 0.2 26.7

Net (decrease) increase in Cash and cash equivalents (839.3) 277.9 (390.5) (871.4)

Cash and cash equivalents at beginning of period 981.1 369.4 532.3 1,518.7

Cash and cash equivalents at end of period $ 141.8 $ 647.3 $ 141.8 $ 647.3

LABCORP HOLDINGS INC. AND SUBSIDIARIES

Condensed Combined Non-GAAP Segment Information

(Dollars in Millions)

Three Months Ended June 30, Six Months Ended June 30,

2026 2025 2026 2025

Diagnostics Laboratories

Revenues $ 2,900.7 $ 2,748.8 $ 5,662.8 $ 5,378.4

Adjusted operating income $ 522.6 $ 482.8 $ 981.3 $ 910.3

Adjusted operating margin 18.0 % 17.6 % 17.3 % 16.9 %

Biopharma Laboratory Services

Revenues $ 836.2 $ 784.8 $ 1,616.8 $ 1,506.1

Adjusted operating income $ 142.2 $ 123.3 $ 262.9 $ 230.2

Adjusted operating margin 17.0 % 15.7 % 16.3 % 15.3 %

Consolidated

Revenues $ 3,731.1 $ 3,527.3 $ 7,268.7 $ 6,872.4

Adjusted segment operating income $ 664.8 $ 606.1 $ 1,244.2 $ 1,140.5

Unallocated corporate expense (76.1) (74.5) (147.6) (139.9)

Consolidated adjusted operating income $ 588.7 $ 531.6 $ 1,096.6 $ 1,000.6

Adjusted operating margin 15.8 % 15.1 % 15.1 % 14.6 %

The consolidated revenue and adjusted segment operating income are presented net of intercompany transaction eliminations and other amounts not used in determining segment performance. Adjusted operating income and adjusted operating margin are non-GAAP measures. See the subsequent reconciliation of non-GAAP financial measures.

LABCORP HOLDINGS INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Measures

(Dollars and Shares in Millions, Except Per Share Data)

Three Months Ended June 30, Six Months Ended June 30,

2026 2025 2026 2025

Adjusted Operating Income

Operating income $ 451.6 $ 394.5 $ 832.4 $ 720.5

Amortization of intangibles and other assets (a)

78.1 68.3 153.7 137.9

Restructuring and other charges (b)

5.1 4.1 11.5 10.5

Acquisition and disposition-related costs (c)

21.3 15.1 31.2 44.2

LaunchPad costs (d)

11.7 17.2 24.7 37.3

Other 20.9 31.9 43.1 46.4

TSA reimbursement (e)

— 0.5 — 3.8

Adjusted operating income $ 588.7 $ 531.6 $ 1,096.6 $ 1,000.6

Adjusted operating profit margin 15.8 % 15.1 % 15.1 % 14.6 %

Adjusted Net Income

Net income $ 298.7 $ 237.9 $ 576.5 $ 450.7

Impact of adjustments to operating income 137.1 137.1 264.2 280.1

Loss on venture fund investments, net (f)

1.5 32.7 8.6 36.1

Equity method loss from SYNLAB investment (g)

6.2 — 11.2 —

TSA reimbursement (e)

— (0.5) — (3.8)

Other 0.6 0.7 (7.9) 0.7

Income tax impact of adjustments (h)

(34.9) (43.4) (91.0) (75.3)

Adjusted net income $ 409.2 $ 364.5 $ 761.6 $ 688.5

Weighted-average diluted common shares outstanding 82.0 83.9 82.4 84.1

Adjusted net income per share $ 4.99 $ 4.35 $ 9.24 $ 8.19

(a) Amortization of intangible assets acquired as part of business acquisitions.

(b) Restructuring and other charges represent amounts incurred in connection with the elimination of redundant positions and facilities and contract termination costs within the organization in connection with our LaunchPad initiatives, and acquisitions or dispositions of businesses by the company.

(c) Acquisition and disposition-related costs include due-diligence legal and advisory fees, retention bonuses, impact of delayed contract or license transfers, and other integration or disposition related activities.

(d) LaunchPad costs include non-capitalized costs associated with the implementation of systems, consolidation of processes, and consulting costs incurred as part of various business process improvement initiatives.

(e) Represents transition services fees charged to Fortrea Holdings Inc. related to administrative and IT systems support. The costs to provide these services are included in operating income but the service fees are included in other income.

(f) The company makes investments in companies or investment funds developing promising technology related to its operations. The company recorded net gains and losses related to several distributions from venture funds, increases in the market value of investments, and impairments of other investments due to the underlying performance of the investments.

(g) Adjustment removes the impact of the equity method income from the Company's minority investment in SYNLAB.

(h) Income tax impact of adjustments calculated based on the tax rate applicable to each item.

GRAPHIC

Filename: labcorp_logoxhorizontalxcoa.jpg · Sequence: 6

Binary file (110565 bytes)

Download labcorp_logoxhorizontalxcoa.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover page

Jul. 30, 2026

Cover page. [Abstract]

Written Communications

false

Entity Address, Address Line One

358 South Main Street

Entity Tax Identification Number

99-2588107

Entity Central Index Key

0000920148

Document Period End Date

Jul. 30, 2026

Entity Registrant Name

LABCORP HOLDINGS INC.

City Area Code

336

Local Phone Number

229-1127

Title of 12(b) Security

Common Stock, $0.10 par value

Trading Symbol

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

Amendment Flag

false

Entity Incorporation, State or Country Code

Entity File Number

1-11353

Entity Address, City or Town

Burlington

Entity Address, State or Province

Entity Address, Postal Zip Code

27215

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Document Type

8-K

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Cover page. [Abstract]

+ References

No definition available.

+ Details

Name:

lh_Coverpage.Abstract

Namespace Prefix:

lh_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration